Medicare覆蓋範圍，癌症復發和確切的科學：改變遊戲規則

精確科學的OnCodetect™測試可確保醫療保險的覆蓋範圍，標誌著大腸癌患者和個性化醫學的關鍵時刻。

Medicare Coverage, Cancer Recurrence, and Exact Sciences: A Game Changer

Medicare覆蓋範圍，癌症復發和確切的科學：改變遊戲規則

Big news in the fight against colorectal cancer! Exact Sciences just got the green light from Medicare for its Oncodetect™ test. This means earlier, more personalized insights for patients. Let's dive into what this means for you.

反腸癌鬥爭的重要新聞！精確的科學剛剛獲得了Medicare的綠燈，以進行OnCodeTect™測試。這意味著對患者的更早，更個性化的見解。讓我們深入了解這對您意味著什麼。

What's the Buzz About Oncodetect™?

OnCodetect™的嗡嗡聲是什麼？

Oncodetect™ is a molecular residual disease (MRD) test. Basically, it's like a super-sensitive detective for cancer. It hunts down tiny traces of cancer cells that might be left behind after treatment. Think of it as a high-tech tool that helps doctors spot recurrence way before traditional methods, potentially up to two years sooner than imaging alone. Pretty slick, huh?

OnCodetect™是一種分子殘留疾病（MRD）測試。基本上，這就像一個癌症的超敏感偵探。它可以追捕治療後可能會留下的癌細胞的微小痕跡。將其視為一種高科技工具，可以幫助醫生在傳統方法之前發現復發的方式，可能比單獨成像要早起來長達兩年。漂亮，吧？

Medicare Says Yes: A Huge Step Forward

Medicare說是：向前邁

The Centers for Medicare & Medicaid Services (CMS) has granted Medicare coverage for Oncodetect™ for patients with stage II, III, and resectable stage IV colorectal cancer. This coverage applies to serial use over five years in adjuvant and recurrence monitoring settings. This is a massive win because it makes this cutting-edge technology accessible to more people who need it. It's a big deal for the over three million Americans eligible for MRD testing across multiple solid tumors.

Medicare＆Medicaid服務中心（CMS）已為II，III期和可切除的IV期結直腸癌的患者授予了OnCodetect™Medicare覆蓋範圍。該覆蓋範圍適用於五年來輔助和復發監控設置的串行使用。這是一個巨大的勝利，因為它使得需要它的更多人可以使用這項尖端的技術。對於有資格在多個實體瘤中進行MRD測試的超過300萬美國人來說，這是一件大事。

Why This Matters

為什麼這很重要

Here’s the deal: early detection is everything. The Oncodetect™ test tracks up to 200 ctDNA variants, helping oncologists make informed decisions during critical treatment moments. Brian Baranick, Executive Vice President and General Manager, Precision Oncology at Exact Sciences, said it best: this coverage expands access to earlier, more personalized insights.

這是交易：早期發現就是一切。 OnCodeTect™測試軌跡多達200個CTDNA變體，幫助腫瘤學家在關鍵治療時刻做出明智的決定。精確科學精確腫瘤學的執行副總裁兼總經理Brian Baranick說，這是最好的：這種覆蓋範圍擴大了對早期，更個性化的見解的訪問權限。

The Science-y Stuff (But Not Too Much)

科學的東西（但不是太多）

The Oncodetect™ test isn't just some flash-in-the-pan technology. It's backed by solid clinical validation, including studies like Beta-CORRECT and Alpha-CORRECT. These studies confirm the test's ability to predict outcomes across different stages of colorectal cancer. Plus, it integrates seamlessly with the ExactNexus™ platform, making it easy to use alongside other Exact Sciences tools.

OnCodetect™測試不僅僅是一些閃光技術。它得到了堅實的臨床驗證的支持，包括β-校正和α-校正等研究。這些研究證實了該測試能夠預測結直腸癌不同階段的結果的能力。另外，它將與Exterrexus™平台無縫集成，從而易於與其他精確科學工具一起使用。

Looking Ahead

展望未來

Exact Sciences isn't stopping here. They're pushing for Medicare coverage across other solid tumor indications, aiming to bring the benefits of MRD testing to even more patients. It's all about improving outcomes and giving people a fighting chance.

確切的科學並沒有停止這裡。他們正在推動其他實體瘤指示的醫療保險覆蓋範圍，旨在將MRD測試的好處帶給更多患者。這一切都是關於改善結果並為人們提供戰鬥機會。

The Bottom Line

底線

Medicare coverage for Oncodetect™ is a game-changer. It means more people have access to advanced technology that can detect cancer recurrence earlier and help doctors make better treatment decisions. It's a win for patients, a win for science, and a win for the future of cancer care.

OnCodetect™的Medicare覆蓋範圍是改變遊戲規則的。這意味著越來越多的人可以使用先進的技術，這些技術可以更早地檢測到癌症的複發並幫助醫生做出更好的治療決定。這是患者的勝利，科學的勝利，也是癌症護理未來的勝利。

So, what’s next? Keep an eye on Exact Sciences. They’re not just sitting back; they’re actively working to make cancer screening and diagnostics better for everyone. And that’s something to smile about, wouldn't you agree?

那麼，下一步是什麼？密切關注確切的科學。他們不只是坐下來；他們正在積極努力為每個人提供更好的癌症篩查和診斷。這是值得微笑的，您不同意嗎？